Javascript must be enabled to continue!
Carbetocin versus Oxytocin in Active Management of 3rd stage of Labour following Vaginal Delivery
View through CrossRef
Background: Every day more than 220 women around the world die from severe bleeding after childbirth. Globally post-partum hemorrhage is the number one direct cause of maternal mortality. Most postpartum hemorrhages are caused by uterine atony and occur in the immediate postpartum period. Most of these tragic deaths can be prevented by active management of third stage of labour. Active management of the third stage of labor should be practiced routinely to decrease the risk of postpartum hemorrhage. Oxytocin is used for enhancing uterine contraction after delivery. But oxytocin has some limitations like shorter half- life, less contraction time and more side effects, whereas carbetocin has prolonged duration of action which ensures more contraction time and less adverse effects. This study was done to see the efficacy and safety of carbetocin over oxytocin for prevention of PPH after vaginal delivery.
Methodology: A randomized controlled clinical trial was conducted in the Department of Obstetrics and Gynecology, Shaheed Suhrawardy Medical College and Hospital, Dhaka, Bangladesh over a period of 9 months from January 2015 to September 2015. Ninety four patients undergoing vaginal delivery at term were randomized into two groups receiving either 10IU oxytocin or 100 μg carbetocin. Outcome measures such as primary PPH, massive blood loss, need for additional uterotonic drug, additional blood transfusion as well as adverse effects were documented.
Results: In this study, massive blood loss did not occur none of patients in carbetocin group. But massive blood loss occured 6.4% women of oxytocin group. Further fundal massage , immediate blood transfusion and additional uterotonics didn’t need any patient in carbetocin group. In oxytocin group, fundal massage required in 8.5% of women, blood transfusion needed in 10.6% patients and additional uterotonics needed in 10.6% women. Average amount of blood loss was 88 ml less in carbetocin group and adverse effects of drugs were almost similar in both group. Primary PPH developed in oxytocin group 8.5% but none of patients had developed PPH in carbetocin group.
Conclusion: Carbetocin is an effective new drug than oxytocin for prevention of postpartum hemorrhage in vaginal delivery.
Bioresearch Commu. 7(1): 927-931, 2021 (January)
Bangladesh Journals Online (JOL)
Title: Carbetocin versus Oxytocin in Active Management of 3rd stage of Labour following Vaginal Delivery
Description:
Background: Every day more than 220 women around the world die from severe bleeding after childbirth.
Globally post-partum hemorrhage is the number one direct cause of maternal mortality.
Most postpartum hemorrhages are caused by uterine atony and occur in the immediate postpartum period.
Most of these tragic deaths can be prevented by active management of third stage of labour.
Active management of the third stage of labor should be practiced routinely to decrease the risk of postpartum hemorrhage.
Oxytocin is used for enhancing uterine contraction after delivery.
But oxytocin has some limitations like shorter half- life, less contraction time and more side effects, whereas carbetocin has prolonged duration of action which ensures more contraction time and less adverse effects.
This study was done to see the efficacy and safety of carbetocin over oxytocin for prevention of PPH after vaginal delivery.
Methodology: A randomized controlled clinical trial was conducted in the Department of Obstetrics and Gynecology, Shaheed Suhrawardy Medical College and Hospital, Dhaka, Bangladesh over a period of 9 months from January 2015 to September 2015.
Ninety four patients undergoing vaginal delivery at term were randomized into two groups receiving either 10IU oxytocin or 100 μg carbetocin.
Outcome measures such as primary PPH, massive blood loss, need for additional uterotonic drug, additional blood transfusion as well as adverse effects were documented.
Results: In this study, massive blood loss did not occur none of patients in carbetocin group.
But massive blood loss occured 6.
4% women of oxytocin group.
Further fundal massage , immediate blood transfusion and additional uterotonics didn’t need any patient in carbetocin group.
In oxytocin group, fundal massage required in 8.
5% of women, blood transfusion needed in 10.
6% patients and additional uterotonics needed in 10.
6% women.
Average amount of blood loss was 88 ml less in carbetocin group and adverse effects of drugs were almost similar in both group.
Primary PPH developed in oxytocin group 8.
5% but none of patients had developed PPH in carbetocin group.
Conclusion: Carbetocin is an effective new drug than oxytocin for prevention of postpartum hemorrhage in vaginal delivery.
Bioresearch Commu.
7(1): 927-931, 2021 (January).
Related Results
Comparative Study between Oxytocin and Carbetocin for the prevention of Primary Postpartum Hemorrhage following Caesarean Section
Comparative Study between Oxytocin and Carbetocin for the prevention of Primary Postpartum Hemorrhage following Caesarean Section
Background & objective: Of the many pharmacological options for the management of postpartum hemorrhage, oxytocin is the first line of treatment. The newer drug carbetocin is g...
Carbetocin and Oxytocin in the Active Management of third Stage of Labor after Vaginal Birth of Baby
Carbetocin and Oxytocin in the Active Management of third Stage of Labor after Vaginal Birth of Baby
Postpartum hemorrhage (PPH) is one of the major contributors to maternal mortality and morbidity worldwide. Active management of the third stage of labor has been proven to be effe...
Prevention of prolonged labour in term nulliparas with oxytocin alone versus with oxytocin and an antispasmodic
Prevention of prolonged labour in term nulliparas with oxytocin alone versus with oxytocin and an antispasmodic
Background: Poor progress of labour is a common problem with nulliparous deliveries. It occurs when the cervical dilatation rate in the active phase of the first stage of labour is...
024 Quiescent Wakefulness: Characterising the Impact of Oxytocin on Sleep-Wake Behaviour in Male and Female Rats
024 Quiescent Wakefulness: Characterising the Impact of Oxytocin on Sleep-Wake Behaviour in Male and Female Rats
Abstract
Introduction
Oxytocin is a versatile hypothalamic neuropeptide involved in diverse neurobehavioural processes. Since ox...
Randomised Control Trial of 3 IU Intravenous Oxytocin Bolus With 7 IU Oxytocin Infusion Versus 10 IU Intramuscular Oxytocin in the Third Stage of Labour in the Prevention of Postpartum Hemorrhage
Randomised Control Trial of 3 IU Intravenous Oxytocin Bolus With 7 IU Oxytocin Infusion Versus 10 IU Intramuscular Oxytocin in the Third Stage of Labour in the Prevention of Postpartum Hemorrhage
Objectives: Intravenous (IV) oxytocin during vaginal delivery has been rarely used since an intramuscular (IM) route or IV infusion have been preferred in this regard. The trial ai...
Advantages of Intramyometrial Carbetocin and Oxytocin in Cesarean Delivery: Preventing PPH While Reducing Ergometrine Use
Advantages of Intramyometrial Carbetocin and Oxytocin in Cesarean Delivery: Preventing PPH While Reducing Ergometrine Use
Background: Postpartum hemorrhage (PPH), primarily caused by uterine atony, remains a leading contributor to maternal mortality. Carbetocin, a long-acting oxytocin analogue, provid...
Comparative evaluation of the caesarean section rate in term nulliparas with labour dystocia following augmentation with oxytocin alone versus with oxytocin and drotaverine
Comparative evaluation of the caesarean section rate in term nulliparas with labour dystocia following augmentation with oxytocin alone versus with oxytocin and drotaverine
Background: Labour dystocia is the commonest indication for emergency caesarean section in nulliparas, and occurs when the progress of labour is abnormally slow. Labour dystocia ma...
The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
Abstract
Background
Around 90% of postmenopausal women are suffering from vaginal atrophy. This study aimed to evaluate t...

